We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+18.58%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$733M
AUM Growth
-$135M
Cap. Flow
-$230M
Cap. Flow %
-31.36%
Top 10 Hldgs %
42.15%
Holding
113
New
16
Increased
22
Reduced
29
Closed
27

Top Buys

Rank Stock Value
1
ORKA
Oruka Therapeutics
ORKA
+$12M
2
NUVL
Nuvalent
NUVL
+$11.4M
3
ALKS icon
Alkermes
ALKS
+$9.33M
4
ARWR icon
Arrowhead Research
ARWR
+$6.71M
5
VRDN icon
Viridian Therapeutics
VRDN
+$6.13M

Top Sells

Rank Stock Value
1
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$20.4M
2
ONC
BeOne Medicines Ltd
ONC
+$13.5M
3
CLDX icon
Celldex Therapeutics
CLDX
+$13.4M
4
MORF
Morphic Holding, Inc. Common Stock
MORF
+$8.54M
5
APGE icon
Apogee Therapeutics
APGE
+$8.25M

Sector Composition

Rank Sector Weight
1 Healthcare 81.54%
2 Financials 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVRA icon
51
Savara
SVRA
$1.13B
$2.97M 0.41%
700,000
-846,850
-55% -$3.74M
NKTX icon
52
Nkarta
NKTX
$184M
$2.94M 0.4%
650,000
+450,000
+225% +$2.56M
MIRM icon
53
Mirum Pharmaceuticals
MIRM
$7.11B
$2.92M 0.4%
75,000
-80,000
-52% -$3.19M
IMTX icon
54
Immatics
IMTX
$1.26B
$2.85M 0.39%
250,000
-50,000
-17% -$592K
SYRS
55
PUT
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.65M 0.36%
+1,234,200
New +$4.43M
BBOT
56
BridgeBio Oncology
BBOT
$675M
$2.61M 0.36%
250,000
– –
CNTX icon
57
Context Therapeutics
CNTX
$56.6M
$2.59M 0.35%
1,321,153
-297,987
-18% -$661K
NARI
58
DELISTED
Inari Medical, Inc. Common Stock
NARI
$2.47M 0.34%
60,000
-140,000
-70% -$6.72M
ROIV icon
59
Roivant Sciences
ROIV
$24.5B
$2.33M 0.32%
201,587
-150,000
-43% -$1.71M
IMVT icon
60
CALL
Immunovant
IMVT
$8.2B
$2.22M 0.3%
78,000
+23,700
+44% +$699K
KZR
61
DELISTED
Kezar Life Sciences
KZR
$1.94M 0.27%
251,178
+75,000
+43% +$452K
CMPS
62
Compass Pathways
CMPS
$1.57B
$1.89M 0.26%
300,512
-200,000
-40% -$1.41M
TECX
63
Tectonic Therapeutic
TECX
$605M
$1.77M 0.24%
58,331
– –
NAMSW icon
64
NewAmsterdam Pharma Warrant
NAMSW
$83.7M
$1.49M 0.2%
212,974
+10,375
+5% +$80.5K
SLNO
65
DELISTED
Soleno Therapeutics
SLNO
$1.26M 0.17%
+25,000
New +$1.2M
JBIO
66
Jade Biosciences
JBIO
$1.2B
$1.25M 0.17%
17,143
+11,429
+200% +$737K
QTTB icon
67
Q32 Bio
QTTB
$346M
$1.24M 0.17%
27,777
– –
VSTM icon
68
Verastem
VSTM
$505M
$1.2M 0.16%
+400,000
New +$1.09M
BMRN icon
69
BioMarin Pharmaceuticals
BMRN
$11.4B
$1.05M 0.14%
+15,000
New +$1.25M
ZURA icon
70
Zura Bio
ZURA
$500M
$907K 0.12%
223,335
– –
PBYI icon
71
Puma Biotechnology
PBYI
$422M
$638K 0.09%
250,000
– –
RPTX
72
DELISTED
Repare Therapeutics
RPTX
$596K 0.08%
+173,351
New +$571K
KYTX icon
73
Kyverna Therapeutics
KYTX
$440M
$586K 0.08%
119,900
-80,100
-40% -$618K
ADGM
74
Adagio Medical Holdings
ADGM
$11.3M
$550K 0.08%
+213,235
New +$1.02M
IMTXW
75
DELISTED
Immatics N.V. Warrants
IMTXW
$431K 0.06%
187,204
– –
1 2
3
4 5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, Affinity Asset Advisors held 113 positions worth $733M, down 16% from $868M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Affinity Asset Advisors withdrew a net $230M in Q3 2024, closing 27 positions and reducing 29 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $20.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 65% a quarter earlier, followed by Financials.

Against the trend, Affinity Asset Advisors opened a new position in Arvinas worth $5.54M.

  • Affinity Asset Advisors's largest Q3 2024 buy was Arvinas: 225,000 shares worth $5.54M.
  • Affinity Asset Advisors added most to Oruka Therapeutics in Q3 2024, an estimated $12M increase.
  • Affinity Asset Advisors's biggest Q3 2024 reduction was BeOne Medicines Ltd, cutting an estimated $13.5M.
  • Affinity Asset Advisors fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $20.4M.
  • Affinity Asset Advisors's ten largest holdings make up 42% of its $733M portfolio in Q3 2024.
  • Affinity Asset Advisors opened 16 new positions and closed 27 in Q3 2024.
  • Affinity Asset Advisors's portfolio value fell 16% quarter-over-quarter to $733M.

Based on Affinity Asset Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.